Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial

BACKGROUND: Due to prophylactic colectomy, mortality in patients with familial adenomatous polyposis (FAP) has changed, with duodenal cancer currently being the main cause of death. Although celecoxib reduces duodenal polyp density in patients with FAP, its long-term use may increase the risk of car...

Descripción completa

Detalles Bibliográficos
Autores principales: van Heumen, Bjorn WH, Roelofs, Hennie MJ, Vink-Börger, M Elisa, Dekker, Evelien, Mathus-Vliegen, Elisabeth MH, Dees, Jan, Koornstra, Jan J, Langers, Alexandra MJ, Nagtegaal, Iris D, Kampman, Ellen, Peters, Wilbert HM, Nagengast,, Fokko M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750541/
https://www.ncbi.nlm.nih.gov/pubmed/23919274
http://dx.doi.org/10.1186/1750-1172-8-118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750541/
https://www.ncbi.nlm.nih.gov/pubmed/23919274
http://dx.doi.org/10.1186/1750-1172-8-118

Ejemplares similares